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a  b  s  t  r  a  c  t
Background  and purpose:  It is  unclear  whether  adaptive  servo-ventilation  (ASV)  is safe  and  effective  in
patients  with  severe  systolic  heart  failure  (HF).  Our  aim  in this  study  was  to estimate  the  safety  and
efﬁcacy  of  ASV  therapy  for patients  with  severe  systolic  HF.
Methods  and subjects:  Seventy-six  HF  patients  (age:  69  ±  12  years;  53 men),  categorized  as  New  York
Heart  Association  (NYHA)  Class  II–IV, with  left ventricular  ejection  fraction  (LVEF)  of <50%,  received  ASV
therapy  after  optimal  medical  therapy  to  determine  the safety  and  efﬁcacy  of ASV. Patients  were  divided
into  2 groups  based  on their  LVEF:  group  L  (LVEF  < 30%;  n = 42) and  group  H  (LVEF  ≥  30%;  n  =  34).  After  6
months  of  ASV  therapy,  we compared  the  changes  in LVEF,  brain  natriuretic  peptide  (BNP),  and  incidence
of  fatal  cardiovascular  events  between  the  groups.
Results: The  groups  differed  signiﬁcantly  with  respect  to  beta-blocker  treatment  before  ASV therapy
(p  <  0.0001).  After  6  months  of ASV  therapy,  LVEF  and  BNP  levels  had  improved  in both  groups.  In  group
L,  LVEF  had  improved  from  24.1  ±  5.6%  to 35.2  ± 10.6%  (p < 0.0001)  and  BNP  from  591  (273–993)  pg/ml
to  142  (39–325)  pg/ml  (p = 0.002).  Moreover,  1-year  follow-up  data  showed  a tendency  toward  improve-
ment  of NYHA  classiﬁcation  in  group  L (group  L: 50%;  group  H: 29%;  p  = 0.07),  and  showed  no signiﬁcant
difference  with  regard  to fatal  cardiovascular  events  between  the  2 groups  (group  L: 11.9%; group  H:
5.9%;  p =  0.36).
Conclusions:  Our  study  demonstrated  that ASV  therapy  is safe  and effective  for  use  in very  severe  systolic
HF patients  as  well  as  in  relatively  mild  systolic  HF patients.
© 2ntroduction
Adaptive servo-ventilation (ASV) was originally developed as
 treatment modality for patients with central sleep apnea (CSA)
nd complex sleep apnea syndrome, but has also been used for
bstructive sleep apnea [1–6]. Sleep disordered-breathing (SDB)
s closely related to cardiovascular disease, including heart failure
HF) [7–14], and is also closely related to the incidence of fatal car-
iovascular events and mortality [15,16]. For treating HF patients,
ontinuous positive airway pressure (CPAP) has been found to be
ffective [17–19]. However, the Canadian Continuous Positive Air-
ay Pressure for Patients with Central Sleep Apnea and Heart
ailure (CANPAP) study found that this treatment did not affect
urvival, and their data showed the existence of non-responders to
PAP among patients who have both CSA and HF [20].
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In recent years, ASV has been used to treat patients with HF. ASV
therapy has beneﬁcial effects on abnormal ventilation; it improves
sympathetic nerve activity by providing appropriate ventilatory
support using expiratory positive airway pressure and a pres-
sure support system [1,21,22]. Furthermore, ASV therapy has been
shown to prevent fatal cardiovascular events and improve survival
in HF patients and is beneﬁcial even in patients who suffer not
only from severe SDB, but also from mild to moderate SDB [23–25].
However, it is unclear whether ASV therapy is safe and effective for
patients who suffer from severe systolic HF with low left ventricular
(LV) function. For this reason, we attempted to determine the safety
and efﬁcacy of ASV therapy in severe systolic HF patients by eval-
uating the adverse events, including fatal cardiovascular events,
and improvement in LV function in HF patients treated with ASV
therapy.
MethodsStudy design and ethical considerations
The present study enrolled 246 consecutive HF patients who
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he New York Heart Association (NYHA) classiﬁcation for the stages
f HF. All procedures were performed at our medical center. After
edical therapy was optimized, full-night polysomnography was
erformed and 76 patients who suffered from systolic HF [left ven-
ricular ejection fraction (LVEF) < 50%] were treated with ASV. We
onitored the patients’ physical status, including improvements
n the LVEF, and brain natriuretic peptide (BNP). The patients were
lassiﬁed into 2 groups based on their LVEF. The group of patients
ith LVEF < 30% was designated as group L, and the other group
ith LVEF ≥ 30% was designated as group H. Forty-two patients
ere classiﬁed into group L and 34 into group H. Entry criteria
n this study are shown in Fig. 1. After ASV therapy, NYHA clas-
iﬁcation and incidence of fatal cardiovascular events including
eath from progressive HF, cardioembolic stroke, and fatal cardiac
rrhythmias were monitored for 1 year.
This study was conducted in accordance with the recommen-
ations of the Declaration of Helsinki (1975), and the protocol was
pproved by the Institutional Review Board. Written informed con-
ent was obtained from each patient at the start of the study.
leep study and treatment devices
For sleep evaluation, all patients who underwent full-night
olysomnography were assessed by digital polygraphy (E-Series
lus; Compumedics, Abbotsville, Australia). Assessment included
onitoring by electroencephalography, electrooculography, and
hin electromyography. Chest and abdominal movements were
onitored using 2 inductive respiratory bands. Airﬂow was
ssessed using a thermistor. Arterial oxygen saturation was  mea-
ured continuously at a sampling frequency of 1 s using a pulse
ximeter with a ﬁnger probe (Nonin 8000J Adult Flex Sensor;
ompumedics). Sleep stages and arousals were scored according
o standard methods [26,27]. Apnea was deﬁned as the complete
ig. 1. Entry criteria in this study. CPAP, continuous positive airway pressure; HOT,
ome oxygen therapy; LVEF, left ventricular ejection fraction.f Cardiology 63 (2014) 302–307 303
cessation of airﬂow lasting for ≥10 s. Hypopnea was  deﬁned as a
decrease in airﬂow of ≥50% for ≥10 s accompanied by desaturation
(3% decrease in arterial oxygen saturation) and/or an electroen-
cephalographic arousal response. The apnea–hypopnea index (AHI)
was deﬁned as the total number of apneas and hypopneas per hour
of sleep.
In this study, ASV (AutoSet-CS; ResMed, Sydney, Australia) was
administered using a full facemask (ResMed). It consisted of 4 cm
H2O expiratory positive airway pressure and a suitable minimum
to maximum inspiratory support, which was within the recom-
mended minimum manufacturer setting range of 3–8 cm H2O.  The
backup respiratory rate was  15 breaths/min.
Data collection
Baseline data included medical history, physical examination,
and biochemical blood examination. Before ASV therapy, venous
blood samples were obtained after overnight fasting and BNP levels
were recorded. Arterial blood samples were obtained for blood gas
analysis with the patients in a supine position and not receiving
supplemental oxygen. Furthermore, 2-dimensional transthoracic
echocardiography was  performed. The LV end-diastolic and end-
systolic dimensions were measured by M-mode echocardiography,
and LVEF was  calculated by the modiﬁed Simpson’s method.
Presence of dyslipidemia was  deﬁned as the recent use of
cholesterol-lowering drugs, a triglyceride value of ≥150 mg/dL, a
low-density lipoprotein cholesterol value of ≥140 mg/dL, and/or a
high-density lipoprotein cholesterol value of <40 mg/dL. Presence
of hypertension was  deﬁned as the recent use of antihypertensive
drugs or blood pressure level of ≥130/80 mmHg, and the presence
of diabetes mellitus was deﬁned as the recent use of insulin or
antidiabetic drugs, a fasting blood glucose value of ≥126 mg/dL,
and/or a hemoglobin A1c value of ≥6.5%.
After ASV therapy, we established the 6-month follow-up data
including LVEF and BNP levels. Furthermore, we  calculated NYHA
classiﬁcation and incidence of fatal cardiovascular events including
death from progressive HF, cardioembolic stroke, and fatal cardiac
arrhythmias and excluding death from other reasons.
Statistical analysis
Continuous data were expressed as mean ± standard deviation
and were compared between the 2 groups using a 2-tailed t-test.
Skewed data were presented as median and inter-quartile range
and analyzed by the Wilcoxon signed-rank test. Categorical data
were expressed as counts (expressed as percentage) and were com-
pared using a chi-square test. The survival rate (fatal cardiovascular
event-free rate) was  calculated by Kaplan–Meier analysis, and a log-
rank test was used to assess the differences between the two study
groups. The signiﬁcance level was set at 5%, and all analyses were
performed using JMP  software (JMP 10; SAS Institute Inc., Cary, NC,
USA).
Results
The study group consisted of 76 HF patients. The mean age
was 69 ± 12 years. After treating the underlying disease in the
acute phase, these 76 patients were treated with ASV. Forty-two
patients were classiﬁed into group L and 34 into group H. Patient
characteristics are presented in Table 1. No signiﬁcant differences
were observed between the 2 groups with regard to gender and
history of coronary risk factors (hypertension, dyslipidemia, dia-
betes mellitus, and smoking). By contrast, a signiﬁcant difference
was noted between the groups with regard to drug therapy (beta-
blocker treatment) (group L: 64%; group H: 9%; p < 0.0001). Before
ASV therapy, signiﬁcant differences were noted between the 2
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Table 1
Patient characteristics.





Age, years 67 ± 14 72 ± 9 0.08
Males, n (%) 32 (76) 21 (62) n.s.
Body mass index, kg/m2 26.4 ± 7.7 23.2 ± 4.8 0.06
Patients on drug therapy
(beta-blocker treatment), n (%)
27 (64) 9 (26) <0.0001
Coronary risk factors, n (%)
Hypertension 27 (64) 26 (76) n.s.
Dyslipidemia 28 (67) 24 (71) n.s.
Diabetes mellitus 18 (43) 18 (53) n.s.
Cigarette smoking 10 (42) 10 (29) n.s.
Left  ventricular ejection fraction, % 24.1 ± 5.6 41.8 ± 8.3 <0.0001
Left  atrial diameter, mm 42.9 ± 9.5 43.3 ± 8.8 n.s.
Blood pressure, mmHg
Systolic 118 ± 15 128 ± 24 0.04
Diastolic 68 ± 10 70 ± 11 n.s.
Blood triglycerides, mg/dL 123 ± 90 122 ± 80 n.s.
High-density lipoprotein
cholesterol, mg/dL
49 ± 17 51 ± 13 n.s.
Low-density lipoprotein
cholesterol, mg/dL
107 ± 41 111 ± 26 n.s.
Fasting blood sugar, mg/dL 121 ± 64 123 ± 62 n.s.





Arterial CO2 tension, mm Hg 36.8 ± 5.0 38.8 ± 4.7 0.10







































Results of polysomnography (sleep study).





True sleep time, min 311 ± 146 296 ± 148 n.s.
Sleep efﬁciency, % 44.8 ± 20.7 40.8 ± 19.7 n.s.
Apnea–hypopnea index, /h 48.9 ± 27.9 35.8 ± 22.2 0.05
Central sleep apnea index, /h 13.2 ± 16.2 7.5 ± 14.5 0.15
Obstructive sleep apnea index, /h 10.1 ± 18.8 4.4 ± 6.4 0.12
Hypopnea index, /h 19.4 ± 15.8 22.0 ± 14.9 n.s.
Baseline oxygen saturation level, % 94.6 ± 2.2 94.8 ± 1.3 n.s.
Minimum oxygen saturation level, % 80.4 ± 6.8 83.3 ± 5.9 n.s.
Cumulative percentage time at a pulse oximetry
Oxygen saturation below 90%, % 8.5 ± 13.0 1.5 ± 2.0 0.01
Oxygen desaturation index
1-year ASV therapy. Fig. 5 shows the survival rate (fatal cardio-
vascular event-free rate) in the present study as determined using
Kaplan–Meier analysis; it was  not signiﬁcantly different betweenata are presented as mean ± standard deviation or number of subjects (%). Skewed
ata were presented as median (inter-quartile range).
roups with regard to LVEF levels (group L: 24.1 ± 5.6%; group H:
1.8 ± 8.3%; p < 0.0001) and systolic blood pressure levels (group
: 118 ± 15 mmHg; group H: 128 ± 24 mmHg; p = 0.04). However,
here were no signiﬁcant differences between the 2 groups with
egard to the results of biochemical blood examination, includ-
ng triglycerides, low-density lipoprotein cholesterol, high-density
ipoprotein cholesterol, fasting blood sugar, BNP levels, and blood
as analysis.
Full-night polysomnography results revealed that the AHI value
n group L was greater than in group H (group L: 48.9 ± 27.9/h;
roup H: 35.8 ± 22.2/h; p = 0.05) before ASV therapy. In addition,
he following parameters showed a tendency toward being greater
n group L: central apnea index (CAI) (group L: 13.2 ± 16.2/h;
roup H: 7.5 ± 14.5/h; p = 0.15) and obstructive apnea index (group
: 10.1 ± 18.8/h; group H: 4.4 ± 6.4/h; p = 0.12). By contrast, the
ypopnea index was non-signiﬁcantly different between the 2
roups (group L: 19.4 ± 15.8/h; group H: 22.0 ± 14.9/h; p = 0.80).
he cumulative percentage time at a pulse oximetry oxygen sat-
ration below 90% was signiﬁcantly greater in group L (group L:
.5 ± 13.0%; group H: 1.5 ± 2.0%; p = 0.01). The oxygen desaturation
ndex at the 4% level was also signiﬁcantly greater in group L (group
: 31.7 ± 19.8/h; group H: 18.9 ± 13.6/h; p = 0.001). Table 2 summa-
izes the various parameters analyzed during polysomnography.
Fig. 2 shows the changes in LVEF and BNP level before and
fter 6 months of ASV therapy. The LVEF and BNP level were sig-
iﬁcantly improved in both groups (Group L: LVEF before ASV
herapy: 24.1 ± 5.6%, after ASV therapy: 35.2 ± 10.6%, p < 0.0001;
NP before ASV therapy: 591 (278–993) pg/ml, after ASV ther-
py: 142 (39–325) pg/ml, p = 0.002; Group H: LVEF before ASV
herapy: 41.8 ± 8.3%, after ASV therapy: 46.1 ± 12.8%, p = 0.01; BNP
efore ASV therapy: 331 (199–811) pg/ml, after ASV therapy:
44 (75–278) pg/ml, p = 0.002). There was no signiﬁcant differ-
nce in changes in BNP between both groups, but changes in
VEF showed signiﬁcant improvement in group L (p = 0.03). Fig. 3
hows the improvements in several SDB parameters, including
HI, after ASV therapy. The AHI showed signiﬁcant improve-
ent in both groups after 6 months of ASV therapy, and mostAt the 4% level, /h 31.7 ± 19.8 18.9 ± 13.6 0.001
Data are presented as mean ± standard deviation.
strikingly so in group L (Group L: before ASV therapy: 48.9 ± 27.9/h;
after ASV therapy: 18.6 ± 16.6/h; p < 0.0001; Group H: before ASV
therapy: 35.8 ± 22.2/h; after ASV therapy: 17.1 ± 17.0/h; p = 0.03).
The CAI also showed signiﬁcant improvement in the group L
(Group L: before ASV therapy: 13.2 ± 16.2/h; after ASV therapy:
1.0 ± 2.3/h; p = 0.007; Group H: before ASV therapy: 7.5 ± 14.5/h;
after ASV therapy: 0.8 ± 1.8/h; p = 0.10). The OAI did not show
signiﬁcant improvement in either group (Group L: before ASV ther-
apy: 10.1 ± 18.8/h; after ASV therapy: 3.7 ± 7.9/h; p = 0.11; Group
H: before ASV therapy: 4.4 ± 6.4/h; after ASV therapy: 1.7 ± 2.9/h;
p = 0.32). There were no signiﬁcant differences in changes in AHI,
CAI, and OAI between both groups. Fig. 4 summarizes NYHA clas-
siﬁcation and fatal cardiovascular events at 1-year follow-up. This
ﬁgure showed a tendency toward improvement of NYHA classiﬁca-
tion in group L (Group L: 50%; Group H: 29%; p = 0.07), and showed
no signiﬁcant difference with regard to fatal cardiovascular events
between the 2 groups (Group L: 11.9%; Group H: 5.9%; p = 0.36).
Table 3 also summarizes types of fatal cardiovascular events afterFig. 2. (A) Left ventricular ejection fraction (LVEF) before and after adaptive servo-
ventilation (ASV) therapy. (B) Brain natriuretic peptide (BNP) levels before and after
ASV therapy.
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Fig. 3. (A) The apnea–hypopnea index (AHI) level before and after adaptive servo-ventilation (ASV) therapy. (B) The central apnea index (CAI) level before and after ASV
therapy.  (C) The obstructive apnea index (OAI) level before and after ASV therapy.
Fig. 4. (A) New York Heart Association classiﬁcation before and after adaptive servo-
ventilation (ASV) therapy. (B) The frequency of fatal cardiovascular events including
death from progressive heart failure, cardioembolic stroke, and fatal cardiac arrhyth-
mias after 1-year ASV therapy.
Table 3







Group L 80 Female Progressive HF 343
80 Male Progressive HF 63
76  Female Fatal cardiac
arrhythmias
59
82 Male Progressive HF 62
83  Male Progressive HF 267
Group H 79 Male Progressive HF 94
76  Female Progressive HF 123
ASV, adaptive servo-ventilation; HF, heart failure.
Fig. 5. Fatal cardiovascular event-free rate.
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Table 4
Adaptive servo ventilation therapy related complications.





LOS due to hypotension, n (%) 0 (0) 0 (0) n.s.
Allergy including skin erosion,
n (%)
2 (4.8) 2 (5.9) n.s.
Inadequate mask ﬁt/facial
mask discomfort, n (%)
0 (0) 0 (0) n.s.
Aspiration pneumonia, n (%) 1 (2.4) 1 (2.9) n.s















































Types and their prevalence, consequences, and presentations. Circulation
1998;97:2154–9.
[9] Moruzzi P, Sarzi-Braga S, Rossi M,  Contini M.  Sleep apnoea in ischaemic heartoth groups (p = 0.237 by log-rank test). Table 4 shows complica-
ions related to ASV therapy including hypotension, skin erosion,
nadequate mask ﬁtting, and aspiration pneumonia; it was  not sig-
iﬁcantly different between both groups.
iscussion
In the present study, we examined ASV therapy data from 76
F patients to determine whether ASV therapy was safe and effec-
ive for patients with severe systolic HF. Our results revealed that
SV therapy improved LVEF and BNP level. Moreover, ASV ther-
py showed good prognosis to prevent fatal cardiovascular events.
PAP is a common device used to treat HF, and previous studies had
uggested that CPAP may  improve both LVEF and heart transplant-
ree survival if CSA was suppressed soon after initiation. Moreover,
t was reported that ASV therapy successfully improved exercise
olerance in patients with HF and Cheyne-Stokes respiration and
hat it was also effective in improving cardiac dysfunction and prog-
osis in patients with chronic HF and Cheyne-Stokes respiration
28,29].
In the present study, we compared the effectiveness of ASV
herapy in patients with severe systolic HF (group L) with that in
atients with a moderate systolic HF (group H). The CANPAP study
howed that CPAP therapy had only limited effects in survival rate
or patients with severe systolic HF [20]. Excessive positive pres-
ure might have a potentially detrimental effect on severe systolic
F. These are the reasons why we made a comparison between
evere and moderate systolic HF to estimate the safety and efﬁcacy
f ASV therapy. According to full-night polysomnography results,
everal SDB parameters, including AHI, were greater before ASV
herapy in patients with severe systolic HF than in patients with
oderate systolic HF. After ASV therapy, these parameters were
igniﬁcantly improved in both groups and the AHI and CAI in group
 were markedly changed (there were no signiﬁcant differences in
hanges in AHI, CAI, and OAI between both groups). Furthermore,
he LVEF and BNP level were also improved in both groups after ASV
herapy, and signiﬁcantly so in patients with severe HF (there was
o signiﬁcant difference in changes in BNP between both groups,
ut changes in LVEF showed signiﬁcant improvement in group L).
hus, these results indicate that ASV therapy is effective for patients
ith severe systolic HF. We  also examined the safety of ASV therapy
or patients with severe systolic HF compared with moderate sys-
olic HF with regard to adverse events and complications related to
SV therapy including hypotension, skin erosion, inadequate mask
tting, and aspiration pneumonia. One-year follow-up data showed
imilar NYHA classiﬁcation improvement and no signiﬁcant differ-
nce with regard to fatal cardiovascular events, and none of them
howed loss of consciousness due to hypotension between the 2
roups. This result indicates that ASV therapy is also sufﬁciently
afe for patients with severe systolic HF.f Cardiology 63 (2014) 302–307
Study limitations
The present study has some limitations. First, this was a single-
center study, and thus, selection bias was a major concern. Second,
it may  be considered that the most important limitation in this
study was  the small number of patients. However, the number
of patients was  large relative to that used in previous ASV stud-
ies [2,5,6,28,30,31]. Nonetheless, more studies examining a larger
number of HF patients treated with ASV therapy should be con-
ducted to provide a better and more accurate estimation of the
efﬁcacy of ASV therapy in HF patients. Third, there was a signiﬁcant
difference between the 2 groups with regard to beta-blocker treat-
ment before ASV therapy. Most of the severe systolic HF patients
(group L) had already taken beta-blockers before commencement
of the study, which may  have affected the rate of fatal cardiovas-
cular events and created a bias if beta-blockers are involved in the
safety and efﬁcacy of ASV. Finally, this was  investigated as study
groups treated with ASV. A control group treated without ASV
should be investigated to estimate the safety and efﬁcacy of ASV
therapy more accurately.
Conclusions
Our study showed that ASV therapy was successful in attaining a
signiﬁcant improvement in LVEF, BNP, and several SDB  parameters,
including AHI, in severe systolic HF patients, thus demonstrating
that ASV is an effective option for treating HF. Furthermore, 1-
year follow-up data showed that ASV therapy is sufﬁciently safe for
patients with severe systolic HF. In conclusion, the effects of ASV are
more marked in patients with more severe LV systolic dysfunction
as indicated above. We  believe that ASV therapy will be recognized
as an effective and safe treatment option for HF, on par with current
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